← Leaderboards
Piwen Wang
Charles R. Drew University Of Med & Sci
$3,420,646
Attributed
$3,420,646
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $743.9K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,420,646 · 4
By mechanism
SC1$1,435,000 · 1
R35$1,083,333 · 1
U54$746,083 · 1
R03$156,230 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsCellsIn VivoDoseIn VitroBiological AvailabilitySignal TransductionPharmaceutical PreparationsNeoplastic CellObesitySignal PathwayInflammationPhytochemicalNatural ProductsMalignant NeoplasmsLignansArctigeninGreater BurdockMolecularPreventionCancer CellAdipocytesDiabetes MellitusLncap
Grant awards (11)
Phase I/II trial of green tea and quercetin in docetaxel chemotherapy$363,452
U54 · FY2025 · MD · contact PI
Signaling mediators of CCL2/CCR2 and natural product discovery$361,250
R35 · FY2025 · GM · contact PI
Phase I/II trial of green tea and quercetin in docetaxel chemotherapy$382,631
U54 · FY2024 · MD · contact PI
Signaling mediators of CCL2/CCR2 and natural product discovery$361,250
R35 · FY2024 · GM · contact PI
Signaling mediators of CCL2/CCR2 and natural product discovery$360,833
R35 · FY2023 · GM · contact PI
Co-targeting obesity in prostate cancer chemoprevention and therapy$358,750
SC1 · FY2022 · GM · contact PI
Co-targeting obesity in prostate cancer chemoprevention and therapy$358,750
SC1 · FY2021 · GM · contact PI
Co-targeting obesity in prostate cancer chemoprevention and therapy$358,750
SC1 · FY2020 · GM · contact PI
Co-targeting obesity in prostate cancer chemoprevention and therapy$358,750
SC1 · FY2019 · GM · contact PI
Increased chemoprevention by a mixture of three phytochemicals in prostate cancer$77,704
R03 · FY2018 · CA · contact PI
Increased chemoprevention by a mixture of three phytochemicals in prostate cancer$78,526
R03 · FY2017 · CA · contact PI